With a Soliris biosimilar showing up in its rearview mirror, Alexion is piling on patents for its superexpensive drug.
Should the FDA cut down drug-risk statements in TV ads? The not-surprising finding of a new agency study—short lists are easier to recall—suggests so.
A drug pricing campaign is heating up in Ohio, recently spawning allegations of “dark money” from the drug industry in politics.
After three years of work, Gilead is set to move into a new manufacturing campus in California which eventually could have 500 employees.
Our readers' nominations for best and worst M&A show dealmaking gambles can pay off—or not. Here's your chance to weigh in.
Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.
Top drugmakers and pharma's industry kept mum in the wake of Merck CEO Ken Frazier's decision to exit a Trump manufacturing panel.
HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.
Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.
Merck CEO Ken Frazier has resigned from President Trump’s Manufacturing Council and issued an indirect criticism of the president in the process.